Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 8:03 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,515 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Hormone Receptor Positive Early Breast Cancer
Interventions: US-sourced oral Femara® + Letrozole SIE, EU sourced oral Femara® + Letrozole SIE; Drug
Lead sponsor: Rovi Pharmaceuticals Laboratories; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Beverly Hills, California • Margate, Florida • Port Orange, Florida

Conditions: Malignant Hyperthermia
Interventions: Whole exome sequencing; Genetic
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Caregiver Anxiety, Caregiver Anxiety Related to Cancer Imaging, Pediatric Oncology
Interventions: Mindful Module Caregiver Packet; Other
Lead sponsor: Kimberley Roche; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Hypertension, Pulmonary, Pulmonary Arterial Hypertension
Interventions: Treprostinil diethanolamine, Standardized meals; Drug · Other
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy
Interventions: Repaglinide, Pirtobrutinib; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Healthy Volunteers in Fed and Fasted State
Interventions: Dexmethylphenidate; Drug
Lead sponsor: Cingulate Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cerebral Neurological Illness
Interventions: Railroad Test, Swamp Test, Presidents Recognition Test, Judgment of Line Orientation, Symbol Span subtest of the Wechsler Memory Scale-IV, Information subtest of the Wechsler Adult Intelligence Scale-IV:, Digit Span subtest of the Wechsler Adult Intelligence Scale-I, Reading subtest of the Wide Range Achievement Test, Symbol Digit Modalities Test:, Dot Counting Test; Diagnostic Test
Lead sponsor: NYU Langone Health; Other
Eligibility: 21 Years and older
Enrollment: 137 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Volunteers
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Schizophrenia
Interventions: Lurasidone HCl; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 1
States / cities: Glendale, California

Conditions: Healthy Volunteers
Interventions: Xanomeline/Trospium Chloride, Lithium, Valproic Acid, Lamotrigine; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Los Alamitos, California

Conditions: Age-related Cognitive Decline
Interventions: MRI; Device
Lead sponsor: Palo Alto Veterans Institute for Research; Other
Eligibility: 45 Years to 100 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Healthy
Interventions: ibuzatrelvir, carbamazepine ER; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Stroke
Interventions: Single-pulse Transcranial Magnetic Stimulation (TMS), Paired-pulse Transcranial Magnetic Stimulation (ppTMS), Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS), Sham Motor Cortex Stimulation; Device
Lead sponsor: Emory University; Other
Eligibility: 40 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Parkinson Disease, Neurodegenerative Diseases, Movement Disorders, Central Nervous System Diseases, Brain Diseases, Basal Ganglia Diseases, Parkinsonian Disorders
Interventions: Participant self-assessment surveys, Phonation, Gait and balance, Memory, Dexterity, Participant open-response writing, Parkinson mPower mobile application; Behavioral · Other
Lead sponsor: Sage Bionetworks; Other
Eligibility: 18 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy
Interventions: MK-6916, Diltiazem; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 37 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy
Interventions: Part A, Part B; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Cypress, California

Conditions: Obesity, Healthy Lifestyle
Interventions: Lifestyle Intervention, Dasatinib 100 MG, Quercetin 1000mg, Placebo, Abdominal adipose tissue biopsy; Other · Drug · Procedure
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Healthy
Interventions: clopidogrel, Matching placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Electronic Cigarette Use
Interventions: RELX ENDS Tobacco Flavor, RELX ENDS Menthol Flavor, Usual Brand Cigarette, Nicorette White Ice Mint nicotine polacrilex gum; Other
Lead sponsor: Cheerain HK Limited; Industry
Eligibility: 22 Years to 59 Years
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Pain
Interventions: a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Disorder of Consciousness, Comatose, Coma; Prolonged, Vegetative State, Minimally Conscious State
Interventions: Functional MRI (fMRI); Diagnostic Test
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Healthy Adults
Interventions: PF-07220060, Itraconazole, Probenecid; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Hearing Loss, Bilateral
Interventions: Parent-Mediated Intervention (PMI); Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 5 Years to 8 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Evanston, Illinois

Conditions: Diabetes Mellitus
Interventions: Insulin Lispro, Regular Human Insulin, rHuPH20; Drug
Lead sponsor: Halozyme Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Chula Vista, California

Search by objective public record fields.

A Study to Compare the Steady-State Bioavailability of Injectable Letrozole SIE and Oral Letrozole in Post-Menopausal Women With Hormone Receptor Positive Early Breast Cancer

Malignant Hyperthermia Registry and Genetic Testing

Easing Scan Anxiety in Pediatric Oncology Caregivers Through Meditation-based Programs

Effect of Food on the Pharmacokinetics of Oral Treprostinil

A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants

Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects

Pilot Study of New Computer-based Neuropsychological Tool: Visual Tests, Touch Responses

Evaluate Taste and Relative Bioavailability of Two Microsphere Formulations of Crizotinib in Healthy Participants

The Bioequivalence Of Two Different Lurasidone Formulations In Patients

A Study to Evaluate the Effects of Lithium, Valproic Acid, and Lamotrigine on the Pharmacokinetics of KarXT and Effects of KarXT on the Pharmacokinetics of Lithium, Valproic Acid, and Lamotrigine in Healthy Participants

Magnetic Resonance Imaging (MRI) and Decline of Aging Aviator Performance

A Study to Learn If the Study Medicine Called Carbamazepine Changes How the Body Processes the Other Study Medicine Ibuzatrelvir in Healthy Adults

Customized Cortical Stimulation Therapy in the Rehabilitation of Stroke Patients

Mobile Parkinson Observatory for Worldwide, Evidence-based Research (mPower)

A Study of the Effect of Multiple Doses of Diltiazem on the Plasma Levels of MK-6916 in Healthy Participants (MK-6916-005)

Surufatinib DDI With a PPI and a CYP3A Inducer

Single Nuclei RNA-seq to Map Adipose Cellular Populations and Senescent Cells in Older Subjects

Food Effect Study on Pharmacodynamic and Bioavailability of Clopidogrel 300/75 mg in Healthy Subjects

Nicotine Uptake, Measures of Abuse Liability, and Puffing Topography With Use of RELX ENDS Products by Smokers

A Crossover Study to Assess the Bioequivalence of Hydrocodone Bitartrate Extended-Release Tablet

Prognostication of Recovery in Early Disorders of Consciousness Study

A Study to Learn About How the Study Medicines Called Itraconazole and Probenecid Change How the Body Processes PF-07220060

Long-Term Outcomes of Early Communication Intervention for Deaf/Hard of Hearing Toddlers

Pharmacokinetic and Glucodynamic Crossover Study of Subcutaneously (SC) Administered Insulin Lispro + Recombinant Human Hyaluronidase (rHuPH20) and Regular Human Insulin + rHuPH20 Compared to Insulin Lispro Alone